TrialHuman vaccines & immunotherapeutics2022

Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU).

Randall Severance et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.